<DOC>
	<DOCNO>NCT01802385</DOCNO>
	<brief_summary>This phase III trial determine whether adjunctive sertraline lead improve survival 18-week survival . There initial phase I/II unmask dose find pharmacokinetic study CSF concentration 172 person conduct August 2013 August 2014 .</brief_summary>
	<brief_title>Adjunctive Sertraline Treatment HIV-Associated Cryptococcal Meningitis</brief_title>
	<detailed_description>This phase III randomize trial evaluate whether sertraline add standard amphotericin-based therapy cryptococcal meningitis , lead improve survival . Cryptococcal meningitis diagnosis make via CSF cryptococcal antigen ( CRAG ) time lumbar puncture ( LP ) confirmation CSF culture . After informed consent , subject meet eligibility requirement able enter study . A non-randomized phase I dose-escalation study first conduct help optimize dose large randomize phase II study . Phase III Design : Subjects randomize standard induction therapy mask placebo sertraline 400mg/day . We use permutated block randomization 1:1 allocation ( n=275 per arm ) . Total anticipated enrollment : 550 subject .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Meningitis , Fungal</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>Cryptococcal meningitis diagnose CSF cryptococcal antigen ( CRAG ) HIV1 infection Ability willingness participant legal guardian/representative provide inform consent Willing receive protocolspecified lumbar puncture Age &lt; 18 year Receipt &gt; =3 dos amphotericin therapy Can unlikely attend regular clinic visit History know liver cirrhosis Presence jaundice Pregnancy Current breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>cryptococcal meningitis</keyword>
	<keyword>cryptococcus</keyword>
	<keyword>meningitis</keyword>
	<keyword>yeast</keyword>
	<keyword>fungus</keyword>
</DOC>